Breast Cancer Screening: Mammograms, Ages, and What the Numbers Mean

Breast cancer screening means having a mammogram, a low-dose breast X-ray, while you feel well, so that cancer can be found earlier than a lump or symptom would reveal it. The aim is narrow and worth stating plainly: not to find every cancer, and not to reassure everyone, but to catch enough early-stage disease in the right age groups that fewer women die of it. Breast cancer is the most commonly diagnosed cancer in women worldwide, which is part of why organised screening exists for it at all ¹.

What a mammogram is and how it works

A mammogram is an X-ray of the breast taken with the tissue gently compressed between two plates. The compression lasts seconds and lets a lower radiation dose produce a clearer image; it is uncomfortable for many women and briefly painful for some, but it is not harmful. Modern units often use digital or 3D (tomosynthesis) imaging, which builds the breast up in thin layers and can make abnormalities easier to separate from normal tissue.

The point of the test is to show changes before they can be felt: small clusters of calcium, distortions in the tissue, or masses a few millimetres across. A radiologist reads the images, and in many programmes a second reader checks them independently to reduce missed findings. Screening is offered to women without symptoms; if you already have a lump, nipple discharge, or a skin change, that needs a diagnostic assessment of the symptom rather than a wait for the next screening round. The line between screening and a diagnostic test matters here as much as in any other programme.

Who is invited, and when

Eligibility is set by age and risk, not by how you feel. Most population programmes invite women roughly 50 to 74, with some starting from 40 to 45, at intervals of 1 to 3 years depending on the country ². The exact ages and gaps differ between guideline bodies because they weigh the same evidence slightly differently, so the honest answer to “when should I start” is a range rather than one number.

Risk shifts the plan. A first-degree relative with breast cancer, an inherited variant such as BRCA1 or BRCA2, or previous chest radiotherapy can move screening earlier, make it more frequent, or add MRI to the mammogram. Women at very high inherited risk are usually managed in a separate, more intensive pathway rather than the general programme, and they are the group for whom starting in the thirties can make sense. For average-risk women, screening before 40 is not generally recommended, partly because cancer is less common at younger ages and partly because denser younger breasts make the test harder to read.

What the benefit actually is

Screening lowers the chance of dying from breast cancer in invited groups, and this is the single fact the whole programme rests on ³. The trial evidence points to a relative reduction in breast cancer deaths of roughly 15 to 20 percent among women offered mammography, though estimates vary by study, era, and how the analysis is done ⁴. Relative numbers can sound larger than the personal effect, so it helps to translate: across many women screened over many years, screening prevents some deaths, detects more cancers at a treatable stage, and for individuals often means less aggressive treatment than a later-stage diagnosis would require.

That benefit is real and is why the test is offered. It is also finite, which is why screening is targeted rather than universal and lifelong.

The harms the numbers do not hide

No screening test is purely beneficial, and breast screening has two costs that deserve plain attention: false positives and overdiagnosis ⁴.

A false positive is an abnormal result that turns out, after further imaging or a biopsy, to be nothing. These are common over a screening lifetime: a meaningful share of women will be recalled at least once for extra views or a biopsy that finds no cancer, with the anxiety and time that involves. Overdiagnosis is subtler and arguably more important. It means finding a cancer that was genuinely present under the microscope but would never have grown enough to cause symptoms or shorten life. Because clinicians usually cannot tell which screen-detected cancers are harmless, overdiagnosis leads to surgery, radiation, or other treatment that carries risk without benefit. Good programmes quantify these harms in their information leaflets and decision aids rather than mention only the lives saved, and a sound decision puts the benefit and the harms side by side.

Dense breasts, and the limits of any single test

Breast density is one of the practical complications of screening. Dense glandular tissue appears white on a mammogram, the same shade as many tumours, which makes cancers harder to see and lowers the test’s sensitivity. Density is also a modest independent risk factor for breast cancer in its own right. Some programmes now record density and may offer supplemental ultrasound or MRI for women with very dense breasts, though whether and how this is done varies considerably by country and is still an area of active debate.

The broader point is that mammography is good but not perfect. It misses some cancers, and an interval cancer can surface between rounds. This is why being familiar with the normal look and feel of your own breasts, and reporting a new lump, a change in shape, skin dimpling, or nipple changes without waiting for the next invitation, sits alongside screening as a second line of defence. The two protect you in different ways. As with cancer screening in general, the most protective approach combines attending the screens you are eligible for with prompt action on anything new.

A practical way to think about it

If you want a starting point: note your age and any family history, check which programme you are eligible for where you live, and take up the invitation if the evidence supports it for your group. Ask what a recall would involve and roughly how often recalls happen, so a callback for extra imaging does not read as a diagnosis. And keep symptom awareness separate from your screening schedule, because a clear mammogram and a watchful eye on changes are doing two different jobs.

This article is general information, not medical advice. Discuss your own breast screening choices with a qualified clinician who knows your history.